Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder

被引:22
|
作者
Evans, Elizabeth A. [1 ]
Yoo, Caroline [2 ]
Huang, David [2 ]
Saxon, Andrew J. [3 ]
Hser, Yih-Ing [2 ]
机构
[1] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Hlth Promot & Policy, 312 Arnold House,715 North Pleasant St, Amherst, MA 01003 USA
[2] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Semel Inst Neurosci & Human Behav, 11075 Santa Monica Blvd,Ste 200, Los Angeles, CA 90024 USA
[3] Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA
关键词
Buprenorphine; Treatment acceptability; access; and utilization; Opioid use disorder; Pharmacotherapy; Longitudinal; MAINTENANCE TREATMENT; PATIENT PERSPECTIVES; METHADONE TREATMENT; ADDICTION; DEPENDENCE; RETENTION; OUTCOMES; MORTALITY; ABUSE; FACILITIES;
D O I
10.1016/j.jsat.2019.08.002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Nationwide efforts seek to address the opioid epidemic by increasing access to medications for opioid use disorder (OUD), particularly with buprenorphine. A poorly understood challenge is that among individuals with OUD who do receive buprenorphine, many do not adhere to the pharmacotherapy long enough to achieve sustained benefits. We aimed to identify factors associated with buprenorphine treatment utilization over time. Methods: We used random-intercept modeling to identify factors associated with buprenorphine treatment utilization over 2 years after first follow-up by 789 individuals with OUD who had participated in a multi-site randomized clinical trial of buprenorphine compared to methadone. Key predictors were participants' reports of buprenorphine treatment accessibility and acceptability (assessed at first follow-up) and their interaction effects, controlling for baseline randomization status, sociodemographics, and other covariates. Results: Approximately 9.3-11.2% of participants utilized buprenorphine treatment over the 2 years of follow-up. Interaction effects indicated that individuals who perceived buprenorphine to be both accessible and acceptable were most likely to use buprenorphine during follow-up, controlling for other factors. In contrast, individuals who perceived buprenorphine to be unacceptable were least likely to use buprenorphine, regardless the level of perceived access to the medication. Buprenorphine treatment utilization was also negatively associated with Hispanic ethnicity, West coast context, and cumulative months receiving methadone treatment and incarceration during follow-up. Conclusions: To engage more individuals with OUD in long-term treatment with buprenorphine, interventions should target buprenorphine treatment acceptability, in addition to increasing buprenorphine access, and tailor efforts to meet the needs of vulnerable populations.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 36 条
  • [31] EFFECTS OF GALCANEZUMAB ON ACUTE MEDICATION USE AND HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH TREATMENT-RESISTANT MIGRAINE: RESULTS FROM A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL (CONQUER)
    Ford, Janet
    Gomez, Julio Pascual
    Stroud, Chad
    Rettiganti, Mallikarjuna
    Estemalik, Emad
    Day, Kathleen
    Ambrosini, Anna
    CEPHALALGIA, 2020, 40 : 45 - 46
  • [32] Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial
    Garland, Eric L.
    Hanley, Adam W.
    Kline, Anna
    Cooperman, Nina A.
    DRUG AND ALCOHOL DEPENDENCE, 2019, 203 : 61 - 65
  • [33] Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER)
    Ambrosini, Anna
    Estemalik, Emad
    Pascual, Julio
    Rettiganti, Mallikarjuna
    Stroud, Chad
    Day, Kathleen
    Ford, Janet
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (06): : 645 - 656
  • [34] Results From the POINT Pragmatic Randomized Trial: An Emergency Department-Based Peer Support Specialist Intervention to Increase Opioid Use Disorder Treatment Linkage and Reduce Recurrent Overdose
    Watson, Dennis P.
    Tillson, Martha
    Taylor, Lisa
    Xu, Huiping
    Ouyang, Fangqian
    Beaudoin, Francesca L.
    O'Donnell, Daniel
    McGuire, Alan B.
    SUBSTANCE USE & ADDICTION JOURNAL, 2024, 45 (03): : 378 - 389
  • [35] Continuous Versus on Demand Treatment of Ankylosing Spondylitis with Diclofenac over 2 Years Does Not Prevent Radiographic Progression of the Spine: Results from a Randomized Prospective Multi-Center Trial
    Sieper, Joachim
    Listing, Joachim
    Poddubnyy, Denis
    Song, In-Ho
    Hermann, Kay-Geert
    Callhoff, Johanna
    Braun, Juergen
    Rudwaleit, Martin
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [36] CONTINUOUS VERSUS ON DEMAND TREATMENT OF ANKYLOSING SPONDYLITIS WITH DICLOFENAC OVER 2 YEARS DOES NOT PREVENT RADIOGRAPHIC PROGRESSION OF THE SPINE - RESULTS FROM A RANDOMIZED PROSPECTIVE MULTI-CENTER TRIAL (ENRADAS)
    Sieper, J.
    Listing, J.
    Poddubnyy, D.
    Song, I. -H.
    Hermann, K. -G.
    Callhoff, J.
    Braun, J.
    Rudwaleit, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 123 - 123